Core Viewpoint - Haina Pharmaceutical is an integrated pharmaceutical research and manufacturing company that provides CXO services and has proprietary product pipelines, ranking second in China for clinical trial approvals and market authorizations [3][4]. Company Overview - Haina Pharmaceutical operates one of the most comprehensive CXO platforms in the industry, covering the entire drug development process from discovery to commercialization [3]. - The company has 242, 331, 383, and 398 ongoing CXO projects as of December 31 for the years 2022, 2023, 2024, and June 30, 2025, respectively [3]. Proprietary Pipeline - In addition to CXO services, Haina Pharmaceutical has proprietary pipelines and has signed 67 drug technology transfer agreements during the historical record period [4]. - Notable projects include Omeprazole Sodium Bicarbonate Suspension and Levofolinate Injection [4]. Financial Performance - Revenue increased from RMB 264.73 million in 2022 to RMB 409.65 million in 2023, and is projected to reach RMB 424.59 million in 2024 [5][6]. - The net profit attributable to the parent company was approximately RMB 59.77 million, RMB 73.02 million, and RMB 53.30 million for the years 2022, 2023, and 2024, respectively [7]. - The overall gross profit margin was 60.1%, 50.3%, and 46.0% for the years 2022, 2023, and 2024, respectively [8]. Industry Overview - The global pharmaceutical market is projected to reach USD 1.542 trillion by 2024, with a compound annual growth rate (CAGR) of 5.1% from 2024 to 2034 [10]. - The Chinese pharmaceutical market is expected to grow to RMB 1.6297 trillion by 2024, with a CAGR of 5.9% from 2024 to 2034 [10]. - The CRO service market in China is anticipated to grow from RMB 52.2 billion in 2020 to RMB 87.8 billion by 2024, with a CAGR of 13.9% [16]. - The small molecule CMO/CDMO service market is projected to increase from RMB 22.6 billion in 2020 to RMB 60 billion by 2024, with a CAGR of 27.6% [19].
海纳医药递表港交所 业务涵盖药物发现、CMC、临床前和临床开发等全链条环节
Zhi Tong Cai Jing·2025-11-10 07:10